Related Experiment Videos
In vitro inhibition of Ras-Raf association by short peptides
1Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, USA.
Abstract:
Seven amino acid peptides were tested as in vitro inhibitors of oncogenic Ras-Raf association. The sequences of these peptides were derived from the H-Ras effector region (amino acids 25 to 51) and the Ras binding domain of Raf-1 (amino acids 64 to 105). Eleven out of the twenty-one Ras 7-mers tested inhibited formation of the Ras-Raf complex by at least 20% at 100 microM. The most potent of these inhibitory peptides contained the effector residues 32 to 37 or 40 to 45. Of the Raf-1 peptides tested, only the 94-ECCAVFR-100 and 95-CCAVFRL-101 peptides were significant inhibitors of Ras-Raf binding. The 95-101 Raf peptide had an IC50 value of 7 microM and also inhibited Ras-RalGDS binding. Analysis of the 95-101 peptide showed that its inhibitory activity required at least one cysteine followed by several hydrophobic residues. Our results demonstrate the feasibility of using small molecules as inhibitors of Ras protein-protein interactions.
Insights
Small molecule peptides were investigated as inhibitors of oncogenic Ras-Raf interactions. Several peptides effectively blocked Ras-Raf complex formation, demonstrating potential for targeted cancer therapies.
Area of Science:
- Molecular Biology
- Oncology
- Drug Discovery
Background:
- Oncogenic Ras-Raf association is a key pathway in cancer development.
- Targeting protein-protein interactions offers a novel therapeutic strategy.
Purpose of the Study:
- To identify small peptides that inhibit Ras-Raf complex formation.
- To explore the potential of peptide inhibitors for Ras-mediated oncogenesis.
Main Methods:
- Synthesis and screening of seven amino acid peptides derived from H-Ras and Raf-1 domains.
- In vitro assays to measure inhibition of Ras-Raf complex formation.
- Determination of IC50 values for potent inhibitors.
Main Results:
- Eleven of twenty-one tested Ras 7-mer peptides inhibited Ras-Raf complex formation by over 20% at 100 microM.
- Peptides containing H-Ras residues 32-37 or 40-45 were most potent.
- Two Raf-1 peptides (94-ECCAVFR-100 and 95-CCAVFRL-101) significantly inhibited binding, with the latter showing an IC50 of 7 microM.
- The 95-101 Raf peptide also inhibited Ras-RalGDS binding.
Conclusions:
- Small peptides can effectively inhibit oncogenic Ras protein-protein interactions.
- Peptide-based inhibitors represent a feasible approach for targeting Ras signaling in cancer.
- Structural analysis suggests specific residues and hydrophobic properties are crucial for inhibitory activity.